COLLEGIUM PHARMACEUTICAL,INC. (NASDAQ:COLL) Files An 8-K Termination of a Material Definitive AgreementItem 1.02 Termination of a Material Definitive Agreement.
On December8, 2017, Collegium Pharmaceutical,Inc. (the “Company”), after a review of its product portfolio in connection with its execution of a license agreement with Depomed to which it expects to license the right to commercialize Nucynta® (tapentadol) Immediate Release and Nucynta® ER (tapentadol) in the U.S., provided written notice to BioDelivery Sciences International,Inc. (“BDSI”) of termination of the License and Development Agreement dated May11, 2016 (the “License Agreement”), which termination will be effective to the terms of such agreement on March8, 2018. Upon such termination of the License Agreement, the Company’s rights to develop and commercialize Onsolis® (fentanyl buccal soluble film), a Transmucosal Immediate-Release Fentanyl film indicated for the management of breakthrough pain in certain cancer patients, will revert to BDSI. A summary of the material terms of the License Agreement was included in the Company’s Current Report on Form8-K filed on May12, 2016, which is incorporated herein by reference and is qualified in its entirety by reference to the full text of the License Agreement (filed as an exhibit to our Quarterly Report on Form10-Q filed with the Commission on August11, 2016).